[1]李琰,尹煜辉,刘宁,等.《永类钤方》中骨伤内服药方的用药规律分析[J].中医正骨,2024,36(04):47-54.
　LI Yan,YIN Yuhui,LIU Ning,et al.Clinical medication rules of the oral prescriptions for treatment of orthopedic traumatologic diseases(TCM)in Yonglei Qianfang[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2024,36(04):47-54.
点击复制

《永类钤方》中骨伤内服药方的用药规律分析()
分享到：

《中医正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第36卷
期数:
2024年04期
页码:
47-54
栏目:
文献研究
出版日期:
2024-04-20

文章信息/Info

Title:
Clinical medication rules of the oral prescriptions for treatment of orthopedic traumatologic diseases(TCM)in Yonglei Qianfang
作者:
李琰; 尹煜辉; 刘宁; 魏戌
中国中医科学院望京医院,北京 100102
Author(s):
LI Yan; YIN Yuhui; LIU Ning; WEI Xu
Wangjing Hospital of CACMS,Beijing 100102,China
关键词:
中医药学文献;  《永类钤方》;  中医骨伤科疾病;  方剂构成;  方剂分析; 计算机辅助;  数据挖掘;  聚类分析
Keywords:
medicine pharmacologic literature(TCM);  Yonglei Qianfang;  orthopedic traumatologic diseases(TCM);  constitution of formula;  formula analysis; computer assisted;  data mining;  cluster analysis
摘要:
目的:分析《永类钤方》中骨伤内服药方的用药规律。方法:收集《永类钤方》中的骨伤内服药方,建立标准化方药数据库。采用Microsoft Office Excel 2019软件统计纳入方剂中组方药物的出现频次、药性、药味、归经和功效,采用SPSS Modeler 18.0软件分析纳入方剂中组方药物的关联规则,采用SPSS Statistics 26.0软件对高频药物进行系统聚类分析。结果:共收集到47首内服药方,涉及162味中药。出现频次≥5的中药共34味,出现频次排前6位的中药依次为当归、川芎、白芷、生川乌、乳香、肉桂。药性出现频次最高的为温,药味出现频次较高的依次为辛、苦、甘,归经主要归肝经、脾经、心经,药物功效出现频次较高的依次为活血化瘀、补虚和解表。对47首骨伤内服药方中的组方药物进行关联规则分析,共得到17条关联规则,增益均>1,支持度最高的关联规则为当归→川芎,置信度为100%的关联规则为当归→肉桂+川芎、当归→肉桂+白芷、当归→没药+川芎; 关联度较强的药对为川芎-当归、当归-肉桂、当归-乳香、白芷-当归、没药-乳香。聚类分析得到新处方3首,分别为川椒-泽兰-甘草-当归-川芎-肉桂、白芷-桔梗-陈皮-赤芍-茴香-生姜-生地黄、独活-生草乌-干姜-羌活-苍术-牛膝-细辛-续断-何首乌-生川乌-白芍-骨碎补-木鳖子仁-乳香-没药-自然铜。结论:《永类钤方》中骨伤内服药方多采用辛温、苦温和甘温之药,常从肝经、脾经、心经论治,以活血化瘀、补虚并兼顾解表为主要治法,以“发散寒邪,通气通血”为主要用药思想。
Abstract:
Objective:To analyze the clinical medication rules of the oral prescriptions for treatment of orthopedic traumatologic diseases(TCM)in Yonglei Qianfang.Methods:The oral prescriptions aimed at treating orthopedic traumatologic diseases(TCM)were extracted from Yonglei Qianfang and a standard database for the prescriptions was established.The occurrence frequency,medicinal property,medicinal flavor,meridian tropism and efficacy of the normalized Chinese herbs(CHs)in the included prescriptions were statistically analyzed by using the Microsoft Office Excel 2019 software; the association rules of the CHs involved in the included prescriptions were analyzed by employing SPSS Modeler 18.0 software; and the high-frequency CHs were then subjected to systematic cluster analysis by using SPSS Statistics 26 software.Results:Forty-seven oral prescriptions were included in the final analysis,involving 162 CHs,among which 34 ones displayed a occurrence frequency of ≥5,and the top 6 ones with a high occurrence frequency included Angelicae Sinensis Radix(TCD),Chuanxiong Rhizoma,Angelicae Dahuricae Radix,Radix Aconiti Kusenzoffii,Olibanum(TCD)and Cinnamomi Cortex.The CHs in the 47 oral prescriptions are often the ones presented with warm property,pungent,bitter and sweet flavors,and mainly act on liver meridians,spleen meridians and heart meridians with the efficacies mainly as promoting blood circulation to remove blood stasis,tonifying deficiency as well as releasing exterior.The association rule analysis on the 47 oral prescriptions aimed at treating orthopedic traumatologic diseases(TCM)yielded 17 association rules,with the gains of>1.The association rule with the highest support was Angelicae Sinensis Radix(TCD)→Chuanxiong Rhizoma,the ones with a confidence of 100% included Angelicae Sinensis Radix(TCD)→Cinnamomi Cortex+Chuanxiong Rhizoma,Angelicae Sinensis Radix(TCD)→Cinnamomi Cortex+Angelicae Dahuricae Radix and Angelicae Sinensis Radix(TCD)→Myrrha+Chuanxiong Rhizoma.The paired-herbs with strong correlation were Chuanxiong Rhizoma-Angelicae Sinensis Radix(TCD),Angelicae Sinensis Radix(TCD)-Cinnamomi Cortex,Angelicae Sinensis Radix(TCD)-Olibanum(TCD),Angelicae Dahuricae Radix-Angelicae Sinensis Radix(TCD)and Myrrha-Olibanum(TCD).The cluster analysis generated 3 new prescriptions,namely pericarpium zanthoxyli-Lycopi Herba Glycyrrhizae Radix et Rhizoma(TCD)-Angelicae Sinensis Radix(TCD)-Chuanxiong Rhizoma-Cinnamomi Cortex,Angelicae Dahuricae Radix-Platycodonis Radix-Citri Reticulatae Pericarpium-Paeoniae Radix Rubra-Foeniculum Vulgare-Zingiberis Rhizoma Recens-Rehmanniae Radix,and Angelicae Pubescentis Radix(TCD)-Aconiti Kusnezoffii Radix-Zingiberis Rhizoma-Notopterygii Rhizoma et Radix-Atractlodis Rhizoma-Achyranthes Bidentatae Radix(TCD)-Asari Radix et Rhizoma(TCD)-Dipsaci Radix-Polygoni Multiflori Radix(TCD)-Radix Aconiti Kusenzoffii-Paeoniae Radix Alba-Drynariae Rhizoma-Momordica cochinchinensis seed-Olibanum(TCD)-Myrrha-Pyritum.Conclusion:The CHs with pungent,bitter and sweet flavors and warm property mainly act on liver meridians,spleen meridians and heart meridians are more preferred in the oral prescriptions aimed at treating orthopedic traumatologic diseases(TCM)in Yonglei Qianfang,which mainly follow the principle of promoting blood circulation to remove blood stasis,tonifying deficiency as well as releasing exterior.The medication rules conform to the thoughts of dispersing cold-pathogen and promoting the flow of Qi and blood.

参考文献/References:

[1] 李仲南.永类钤方[M].王均宁,整理.北京:人民卫生出版社,2006.
[2] 国家药典委员会.中华人民共和国药典(2020年版 一部)[M].北京:中国医药科技出版社,2020.
[3] 国家中医药管理局《中华本草》编委会.中华本草[M].上海:上海科学技术出版社,1999.
[4] 南京中医药大学.中药大辞典[M].上海:上海科学技术出版社,2006.
[5] 钟赣生,杨柏灿.中药学[M].11版.北京:中国中医药出版社,2021.
[6] 于文忠.《永类钤方》在伤科方面的主要成就[J].中医杂志,1981,22(6):6-8.
[7] 吕成龙,李会会,史永洁,等.中药当归现代研究进展及其质量标志物的预测分析[J].中国中药杂志,2022,47(19):5140-5157.
[8] 张莹莹,张科,宋崟,等.“川芎-当归”药对主要活性成分的网络药理学研究[J].安徽医药,2023,27(1):19-24.
[9] 黄克松,郑昊天,高向明,等.基于网络药理学和分子对接探析当归-川芎药对治疗股骨头坏死的作用机制[J].中医临床研究,2023,15(25):15-20.
[10] 刘力榕,贾志鑫,闫晓宁,等.川芎对白芷中4种香豆素类化合物吸收及清除的影响[J].药学学报,2021,56(7):1804-1810.
[11] 祁建华,明洪,张会择,等.基于数据挖掘法探讨《世医得效方》中治伤方剂的用药规律[J].中医正骨,2022,34(3):20-25.
[12] 黄明翥,周红海,何心愉,等.《医宗金鉴·正骨心法要旨》中治疗伤科瘀肿疼痛方剂的用药规律分析[J].中医正骨,2023,35(10):37-41.
[13] 周世博,赵赫,俞兴.基于数据挖掘探讨《伤科补要》治伤用药规律研究[J].中国医药导报,2023,20(17):4-8.
[14] 曾格格,刘毅,刘天琪,等.基于GC-MS和网络药理学探讨当归-肉桂药对的抗炎作用机制[J].湖北农业科学,2022,61(18):113-119.
[15] 李佳晌,赵子樟,缪晓冬,等.基于网络药理学-分子对接研究乳香-没药配伍改善类风湿性关节炎的作用机制[J].中国中药杂志,2021,46(10):2371-2379.
[16] 曹旭含,白子兴,孙承颐,等.“乳香-没药”治疗膝骨关节炎网络药理学分析[J].中国组织工程研究,2021,25(5):746-753.
[17] 陈婷,宿树兰,钱叶飞,等.乳香-没药配伍前后汤液理化参数变化与化学成分的关联分析[J].中成药,2012,34(8):1529-1536.
[18] 项想,潘承蓉,高茹梦,等.基于UPLC-TQ/MS联用技术分析乳香配伍没药后对乳香中化学成分溶出的影响[J].药物分析杂志,2018,38(4):590-597.
[19] 赵子樟,李佳晌,宿树兰,等.基于网络药理学及细胞实验的乳香-没药功效成分抗炎机制研究[J].中国中药杂志,2021,46(21):5674-5682.
[20] 赵丽辉,赵子樟,李佳晌,等.乳香、没药活性成分KTDA、FSA及其配伍的抗炎镇痛作用及机制研究[J].中药新药与临床药理,2022,33(11):1460-1465.
[21] 黄晨存,严晟,赵元,等.赤芍抗凝血活性成分的筛选[J].中国药物化学杂志,2023,33(3):181-190.
[22] 吴明权,彭伟,周许,等.生地黄活血化瘀功效本草考证及临床应用进展[J].中华中医药杂志,2020,35(7):3553-3556.
[23] 王聃,侯婧霞,吴育,等.自然铜及其煅淬品中金属元素对促进成骨细胞增殖的谱效关系研究[J].中药新药与临床药理,2021,32(8):1109-1113.
[24] 陈玄,陈娟,谢丽华,等.骨碎补-续断药对对成骨/破骨代谢的双向调控作用及其对Hif1ɑ基因的影响[J].中国骨质疏松杂志,2023,29(1):64-69.
[25] 卢钰,保超宇,李具宝,等.基于网络药理学探讨独活-羌活-细辛治疗膝骨关节炎的作用机制[J].云南中医学院学报,2022,45(3):74-84.

相似文献/References:

[1]徐道情,黄维琛,欧梁,等.基于中医传承辅助平台挖掘《正体类要》中治伤内服方剂的用药规律[J].中医正骨,2021,33(12):14.
　XU Daoqing,HUANG Weichen,OU Liang,et al.A data mining-based analysis of clinical medication rules of oral prescriptions for treatment of orthopedic and traumatic diseases in Classification and Treatment of Traumatic Diseases using traditional Chinese medicine inheritance support system[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(04):14.
[2]王笑青,张丽丽,沙莎,等.基于中医传承辅助平台挖掘《辨证录》中痹病内服方剂的组方配伍规律[J].中医正骨,2023,35(06):44.
　WANG Xiaoqing,ZHANG Lili,SHA Sha,et al.A data mining-based analysis of clinical medication rules of oral prescriptions for treatment of Bi-diseases in Syndrome Differentiation Record using traditional Chinese medicine inheritance support system[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2023,35(04):44.
[3]黄明翥,周红海,何心愉,等.《医宗金鉴·正骨心法要旨》中治疗伤科瘀肿疼痛方剂的用药规律分析[J].中医正骨,2023,35(10):37.
　HUANG Mingzhu,ZHOU Honghai,HE Xinyu,et al.A data mining-based analysis of clinical medication rules of traumatologic prescriptions for treatment of blood stasis,swelling and pain in Yizong Jinjian,Essentials of Bone Orthopedics[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2023,35(04):37.

备注/Memo

备注/Memo:
基金项目:中国中医科学院科技创新工程重大攻关项目(CI2021A02013) 通讯作者:魏戌 E-mail:weixu.007@163.com
更新日期/Last Update: 1900-01-01